Post-Approval Excipient Source Change for a Generic Tablet
A marketed immediate-release 500 mg tablet uses microcrystalline cellulose (MCC) PH102 as a dry binder/filler. The approved supplier notifies a source change from wood pulp to cotton linter and a material shift: D50 falls from 110 to 85 µm, bulk density rises from 0.28 to 0.34 g/mL, and crystallinity rises from 78% to 82%. The old supplier will stop supplying in three months. The site has one exhibit batch with the new MCC and three months of 40°C/75% RH stability. Dissolution at 30 min is 92% versus 96% historically; f2 is 48. The product is approved in the US and EU, annual demand is 20 million tablets, and inventory covers 10 weeks. The site proposes immediate implementation and a post hoc stability commitment.
1. Assess the change and determine what regulatory and technical data are needed before implementation.
Read the worked answer
MCC is compendial, but these are not minor attributes. A shift to finer, denser, more crystalline MCC can change granulation water demand, compactability, tablet hardness, disintegration, and dissolution. The source change should be handled through change control with a risk assessment and a formal regulatory classification. In the US, an excipient source change for an approved generic may require a prior-approval supplement or a CBE-30 depending on the effect; in the EU, it is a variation with a defined classification. Because f2 is 48, the new material is not demonstrated to be equivalent, so immediate implementation under a notification alone is not defensible. The data package should include material characterization, a side-by-side exhibit batch, process parameters, tablet properties, dissolution profiles in multiple media, assay and related substances, and stability. The regulatory filing must be prepared before commercial release.
2. Evaluate the sufficiency of one exhibit batch and three months of accelerated stability with f2 = 48.
Read the worked answer
Three months of accelerated data can support an ongoing study, but it is not sufficient to release a major excipient change. One exhibit batch does not establish process robustness, especially when the material attributes have shifted. More importantly, f2 = 48 is below the usual 50 threshold, so similarity is not demonstrated. The 92% versus 96% at 30 min may look modest, but the profile shape, early time points, and variability matter. The site should not treat a post hoc stability commitment as a substitute for pre-implementation data. A defensible package would include at least three batches or a justified bracketing approach, six months of accelerated data, long-term data, and a comparison against the old material. If dissolution remains dissimilar, reformulation or process adjustment is needed before filing.
3. Propose a bridging and supply-continuity plan that protects the market supply.
Read the worked answer
Start with a risk assessment and a material-attribute criticality map. Obtain sufficient old MCC to bridge the change, and quarantine new MCC until approved. Run side-by-side batches with old and new material, then adjust granulation water, mixing time, and compression force only within a design space supported by data. Compare dissolution profiles, hardness, friability, disintegration, and stability. File the appropriate variation or supplement early, using the 10-week inventory and supplier allocation to cover review time. Qualify a second MCC source to avoid a single point of failure. Use a formal management-of-change plan with clear hold points: material approval, exhibit batch approval, stability review, regulatory approval, and commercial release. Do not use the 20 million tablet demand as a reason to skip the science.